Diazabenzo[de]anthracen-3-one compounds and methods for inhibiting PARP
View Patent ↗The present invention relates to diazabenzo[de]anthracen-3-one compounds which inhibit poly(ADP-ribose) polymerase (“PARP”), compositions containing these compounds and methods for using these PARP inhibitors to treat, prevent and/or ameliorate the effects of the conditions described herein.
1. A compound selected from:
pharmaceutically acceptable salts, esters, and mixtures thereof.
2. The compound of claim 1 that is
3. A method of treating diseases or conditions selected from the group consisting of neural tissue damage resulting from ischemia and reperfusion injury, depression, arthritis, inflammatory bowel disorders, gout, chronic pain, acute pain, neuropathic pain, renal failure, retinal ischemia, and septic shock, comprising administering to said animal an effective amount of a compound selected from the group consisting of:
pharmaceutically acceptable salts, esters, and mixtures thereof.
4. The method of claim 3 , wherein said ischemia or reperfusion injury is cerebral injury after cardiac arrest and cardio-pulmonary resuscitation.
5. The method of claim 3 , wherein the septic shock is endotoxic shock.
6. The method of claim 3 , wherein the inflammatory bowel disorder is colitis.
7. The method of claim 3 , wherein the inflammatory bowel disorder is Crohn's disease.
8. A method of radiosensitizing tumor cells in a mammal in need of radiation therapy, comprising: administering to said mammal a compound selected from
pharmaceutically acceptable salts, esters, and mixtures thereof; in an amount sufficient to sensitize said tumor cells to the effects of said radiation therapy.
9. The method of claim 8 wherein the compound is
10. The method of claim 8 wherein the tumor cells are selected from the group consisting of ACTH-producing tumors, acute lymphocytic leukemia, acute nonlymphocytic leukemia, cancer of the adrenal cortex, bladder cancer, brain cancer, breast cancer, cervical cancer, chronic lymphocytic leukemia, chronic myelocytic leukemia, colorectal cancer, cutaneous T-cell lymphoma, endometrial cancer, esophageal cancer, Ewing's sarcoma, gallbladder cancer, hairy cell leukemia, head and neck cancer, Hodgkin's lymphoma, Kaposi's sarcoma, kidney cancer, liver cancer, lung cancer (small and/or non-small cell), malignant peritoneal effusion, malignant pleural effusion, melanoma, mesothelioma, multiple myeloma, neuroblastoma, non-Hodgkin's lymphoma, osteosarcoma, ovarian cancer, ovary (germ cell) cancer, prostrate cancer, pancreatic cancer, penile cancer, retinoblastoma, skin cancer, soft-tissue sarcoma, squamous cell carcinomas, stomach cancer, testicular cancer, thyroid cancer, trophoblastic neoplasms, uterine cancer, vaginal cancer, cancer of the vulva and Wilm's tumor.
11. The method of claim 8 wherein the mammal is human.
12. A method of therapy comprising: chemosensitizing tumor cells in a mammal in need of chemotherapy by administering to said mammal a compound selected from
pharmaceutically acceptable salts, esters, and mixtures thereof; in an amount sufficient to sensitize said tumor cells to the effects of at least one chemotherapeutic agent.
13. The method of claim 12 , wherein said chemosensitizing compound is
14. The method of claim 12 , wherein said mammal is a human.
15. The method of claim 12 , further comprising, first: allowing a time period following administration of said compound to provide an effective amount of chemosensitization, and, second: administering to said mammal a pharmaceutically-effective dose of said chemotherapeutic agent.
16. The method of claim 12 , wherein said compound is administered in a pharmaceutical composition comprising said compound and a pharmaceutically acceptable carrier, diluent, or excipient.
17. The method of claim 12 , further comprising administering to said mammal a therapeutically-effective dose of said chemotherapeutic agent, wherein said chemosensitizing compound and said chemotherapeutic agent are administered essentially simultaneously.
18. The method of claim 12 , wherein said chemotherapeutic agent is selected from the group consisting of temozolomide, adriamycin, camptothecin, carboplatin, cisplatin, daunorubicin, docetaxel, doxorubicin, interferon (alpha, beta, gamma), interleukin 2, irinotecan, paclitaxel, topotecan, therapeutically effective analogs and derivatives of the same, and mixtures thereof.
19. The method of claim 18 , wherein said chemotherapeutic agent is temozolomide.
20. A pharmaceutical composition comprising a therapeutically effective amount of at least one compound selected from the group consisting of,
pharmaceutically acceptable salts, esters, and mixtures thereof; and a pharmaceutically acceptable carrier, diluent, or excipient.
21. The pharmaceutical composition of claim 20 , wherein the compound is
22. The pharmaceutical composition of claim 20 , further comprising a chemotherapeutically effective amount of at least one chemotherapeutic agent, wherein the chemotherapeutic agent is selected from a taxoid, temozolomide, dactinomycin, danorubicin, doxorubicin, 4′-deoxydoxorubicin, bleomycin, pilcamycin, mitomycin, neomycin and gentamycin, etoposide, 4-OH cyclophosphamide, a platinum coordination complex, and mixtures thereof.
23. The pharmaceutical composition of claim 22 wherein said chemotherapeutic agent is temozolomide.